micro-community-banner
 
  • Saved

2yr
SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell Lymphoma - PubMed

SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell Lymphoma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37268478/

In this article, we will review current strategies for the front-line management of mantle cell lymphoma, an uncommon and biologically and clinically heterogeneous subtype of non-Hodgkin lymphoma that remains incurable...

Relevance: In this article, we will review current strategies for the front-line management of mantle cell lymphoma, an uncommon and biologically and clinically heterogeneous subtype of non-Hodgkin lymphoma that remains incurable with current therapies. Patients invariably relapse with time, and as a result, treatment strategies involve...

  • Saved

2yr
Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus - PubMed

Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37300279/

Constitutive activation of the PI3K/AKT/mTOR-pathway plays an important role in the pathogenesis of mantle cell lymphoma (MCL), leading to approval of the mTOR inhibitor temsirolimus for relapsed or refractory MCL....

Summary: We showed for the first time that overexpression of Met plays an important role for mediating temsirolimus resistance in MCL and that pharmacological inhibition of Met signaling could effectively increase sensitivity to mTor inhibition. Combination of crizotinib and temsirolimus could completely overcome acquired temsirolimus...

  • Saved

2yr
Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis - PubMed

Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37278284/

During the period ending in 2020, patients relapsed frequently, incurring high HRU and costs across LoTs. More effective treatments with long-lasting remissions in R/R MCL may reduce healthcare burden.

Conclusions: During the period ending in 2020, patients relapsed frequently, incurring high HRU and costs across LoTs. More effective treatments with long-lasting remissions in R/R MCL may reduce healthcare burden.

  • Saved

2yr
LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA... | Oncotarget

LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA... | Oncotarget

Source : https://www.oncotarget.com/article/28454/text/

https://doi.org/10.18632/oncotarget.28454 Jianli Zhou, Drew Sturtevant, Cassie Love, Aditya Kulkarni, Neha Biyani, Umesh Kathad, Elizabeth Thacker, Sandeep Dave, Kishor Bhatia

Discussion: In the current study, we demonstrated the new acylfulvene compound LP-284 has anti-tumor activity ….

  • Saved

2yr
A Summary of The 2023 European Hematology Association Hybrid Congress

The 2023 European Hematology Association Hybrid Congress took place in Frankfurt, Germany, from June 8 to 11. Sessions covered leukemia, lymphoma, platelet and bleeding disorders, hemophilia, myeloma, thrombosis, transfusions, and stem cell transplantation.

Click to access a post-conference wrap-up report from our team of analysts.